Cassava Sciences Faces Fallout as Alzheimer's Drug Trial Fails

Cassava Sciences' Alzheimer's drug, simufilam, has failed in a large clinical trial, proving to be no more effective than a placebo. This outcome is particularly devastating for the nearly 2,000 participants involved, as the drug was based on falsified research and misleading claims. The failure highlights the ongoing challenges in Alzheimer's drug development and the significant time lost for those who participated in the trials.